ATE154947T1 - Oligonukleotide zur modulation der effekte von cytomegalovirusinfektionen - Google Patents

Oligonukleotide zur modulation der effekte von cytomegalovirusinfektionen

Info

Publication number: ATE154947T1
Authority: AT; Austria
Prior art keywords: cmv; oligonucleotides; modulating; effects; pct
Prior art date: 1990-08-16

Application number

AT91914366T

Other languages

English (en)

Inventor

Kevin P Anderson

Kenneth G Draper

Original Assignee

Isis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-08-16

Filing date

1991-08-14

Publication date

1997-07-15

1991-08-14 Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc

1997-07-15 Application granted granted Critical

1997-07-15 Publication of ATE154947T1 publication Critical patent/ATE154947T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
206010011831 Cytomegalovirus infection Diseases 0.000 title 1
241000701022 Cytomegalovirus Species 0.000 abstract 5
108020004999 messenger RNA Proteins 0.000 abstract 2
108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 abstract 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 abstract 1
241000701024 Human betaherpesvirus 5 Species 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Virology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Biophysics (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Plant Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Analytical Chemistry (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT91914366T 1990-08-16 1991-08-14 Oligonukleotide zur modulation der effekte von cytomegalovirusinfektionen ATE154947T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US56836690A	1990-08-16	1990-08-16

Publications (1)

Publication Number	Publication Date
ATE154947T1 true ATE154947T1 (de)	1997-07-15

Family

ID=24270996

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT91914366T ATE154947T1 (de)	1990-08-16	1991-08-14	Oligonukleotide zur modulation der effekte von cytomegalovirusinfektionen

Country Status (16)

Country	Link
US (1)	US5591720A (de)
EP (1)	EP0544713B1 (de)
JP (1)	JP2708960B2 (de)
KR (1)	KR970005273B1 (de)
AT (1)	ATE154947T1 (de)
AU (1)	AU649717B2 (de)
BR (2)	BR9106751A (de)
CA (1)	CA2089666C (de)
DE (1)	DE69126710T2 (de)
DK (1)	DK0544713T3 (de)
ES (1)	ES2104717T3 (de)
FI (1)	FI930658L (de)
GR (1)	GR3024873T3 (de)
HU (1)	HUT63430A (de)
NO (1)	NO930515L (de)
WO (1)	WO1992003456A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1223831A (en)	1982-06-23	1987-07-07	Dean Engelhardt	Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US5789573A (en) *	1990-08-14	1998-08-04	Isis Pharmaceuticals, Inc.	Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
US6153595A (en) *	1990-08-16	2000-11-28	Isis Pharmaceuticals Inc.	Composition and method for treatment of CMV infections
US5595978A (en) *	1990-08-16	1997-01-21	Isis Pharmaceuticals, Inc.	Composition and method for treatment of CMV retinites
US7119184B2 (en) *	1991-08-12	2006-10-10	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6369209B1 (en)	1999-05-03	2002-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
CA2159639A1 (en) *	1993-04-02	1994-10-13	Vincent J. Miles	Method for selective inactivation of viral replication
US6824976B1 (en)	1993-04-02	2004-11-30	Rigel Pharmaceuticals, Inc.	Method for selective inactivation of viral replication
US6727230B1 (en)	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US5801235A (en) *	1994-05-25	1998-09-01	Hybridon, Inc.	Oligonucleotides with anti-cytomegalovirus activity
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
WO1996002555A1 (en)	1994-07-15	1996-02-01	The University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
WO1997033992A1 (en) *	1996-03-14	1997-09-18	Hybridon, Inc.	Selected oligonucleotides with anti-cytomegalovirus activity
WO1997048795A2 (en) *	1996-06-18	1997-12-24	Hybridon, Inc.	Compositions and methods for treating specific gene expression-related diseases and disorders in humans
EP0855184A1 (de)	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US6576752B1 (en)	1997-02-14	2003-06-10	Isis Pharmaceuticals, Inc.	Aminooxy functionalized oligomers
US6172209B1 (en)	1997-02-14	2001-01-09	Isis Pharmaceuticals Inc.	Aminooxy-modified oligonucleotides and methods for making same
US6127533A (en) *	1997-02-14	2000-10-03	Isis Pharmaceuticals, Inc.	2'-O-aminooxy-modified oligonucleotides
WO1998037919A1 (en)	1997-02-28	1998-09-03	University Of Iowa Research Foundation	USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998046740A1 (en) *	1997-04-17	1998-10-22	Antivirals, Inc.	Method of treating restenosis by antisense targeting of cmv
AU7690898A (en)	1997-05-20	1998-12-11	Ottawa Civic Hospital Loeb Research Institute	Vectors and methods for immunization or therapeutic protocols
US6133246A (en) *	1997-08-13	2000-10-17	Isis Pharmaceuticals Inc.	Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US5877309A (en)	1997-08-13	1999-03-02	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides against JNK
US20070149472A1 (en) *	1997-08-13	2007-06-28	Mckay Robert	Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US6218371B1 (en)	1998-04-03	2001-04-17	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6841539B1 (en)	1998-05-21	2005-01-11	Isis Pharmaceuticals, Inc.	Compositions and methods for topical delivery of oligonucleotides
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6277967B1 (en)	1998-07-14	2001-08-21	Isis Pharmaceuticals, Inc.	Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
US6242589B1 (en)	1998-07-14	2001-06-05	Isis Pharmaceuticals, Inc.	Phosphorothioate oligonucleotides having modified internucleoside linkages
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
US6335194B1 (en)	1998-09-29	2002-01-01	Isis Pharmaceuticals, Inc.	Antisense modulation of survivin expression
PT1152009E (pt)	1999-02-12	2005-03-31	Sankyo Co	Novos analogos de nucleosidos e oligonucleotidos
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
JP4151751B2 (ja) *	1999-07-22	2008-09-17	第一三共株式会社	新規ビシクロヌクレオシド類縁体
US6147200A (en) *	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
WO2001097843A2 (en)	2000-06-22	2001-12-27	University Of Iowa Research Foundation	Methods for enhancing antibody-induced cell lysis and treating cancer
WO2003020884A2 (en)	2001-08-14	2003-03-13	The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services	Method for rapid generation of mature dendritic cells
ES2314099T3 (es)	2001-08-17	2009-03-16	Coley Pharmaceutical Gmbh	Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.
AU2002366710A1 (en)	2001-12-20	2003-07-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
KR20040008342A (ko) *	2002-07-18	2004-01-31	한국전력공사	산업용 보일러의 화학세정시 발생하는 폐액 재활용 방법
JP2005538186A (ja) *	2002-09-13	2005-12-15	レプリコールインコーポレーティッド	非配列相補性の抗ウイルス性オリゴヌクレオチド
US20050196382A1 (en) *	2002-09-13	2005-09-08	Replicor, Inc.	Antiviral oligonucleotides targeting viral families
CA2503693A1 (en)	2002-10-29	2004-05-13	Coley Pharmaceutical Group, Ltd.	Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
EP2530157B1 (de) *	2003-07-31	2016-09-28	Regulus Therapeutics Inc.	Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von miRNAs
CA2842580A1 (en)	2011-07-22	2013-01-31	Public University Corporation Yokohama City University	Technique for cleaving out part of poly(a) chain and/or 3'-terminal sequence of mrna to inhibit translation reaction
SG11201705312PA (en)	2014-12-29	2017-07-28	Bonac Corp	Composition containing nucleic acid molecule stably
AU2016355468B2 (en) *	2015-11-20	2022-12-15	Oregon Health & Science University	CMV vectors comprising microRNA recognition elements
WO2019241435A1 (en) *	2018-06-12	2019-12-19	The J. David Gladstone Institutes	Compositions for herpesvirus transcriptional feedback circuit disruption and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5248670A (en) *	1990-02-26	1993-09-28	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides for inhibiting herpesviruses

1991
- 1991-08-14 WO PCT/US1991/005815 patent/WO1992003456A1/en not_active Ceased
- 1991-08-14 AT AT91914366T patent/ATE154947T1/de not_active IP Right Cessation
- 1991-08-14 JP JP3513776A patent/JP2708960B2/ja not_active Expired - Lifetime
- 1991-08-14 KR KR1019930700439A patent/KR970005273B1/ko not_active Expired - Fee Related
- 1991-08-14 AU AU84393/91A patent/AU649717B2/en not_active Ceased
- 1991-08-14 DE DE69126710T patent/DE69126710T2/de not_active Expired - Fee Related
- 1991-08-14 HU HU93398A patent/HUT63430A/hu unknown
- 1991-08-14 US US07/927,506 patent/US5591720A/en not_active Expired - Lifetime
- 1991-08-14 FI FI930658A patent/FI930658L/fi not_active Application Discontinuation
- 1991-08-14 EP EP91914366A patent/EP0544713B1/de not_active Expired - Lifetime
- 1991-08-14 BR BR919106751A patent/BR9106751A/pt not_active Application Discontinuation
- 1991-08-14 CA CA002089666A patent/CA2089666C/en not_active Expired - Lifetime
- 1991-08-14 DK DK91914366.9T patent/DK0544713T3/da active
- 1991-08-14 ES ES91914366T patent/ES2104717T3/es not_active Expired - Lifetime
1993
- 1993-02-12 NO NO93930515A patent/NO930515L/no unknown
1997
- 1997-05-14 BR BR1100909-8A patent/BR1100909A/pt active IP Right Grant
- 1997-09-26 GR GR970402519T patent/GR3024873T3/el unknown

Also Published As

Publication number	Publication date
US5591720A (en)	1997-01-07
EP0544713A1 (de)	1993-06-09
CA2089666A1 (en)	1992-02-17
NO930515L (no)	1993-03-31
BR9106751A (pt)	1993-08-17
JPH06501841A (ja)	1994-03-03
EP0544713B1 (de)	1997-07-02
BR1100909A (pt)	2000-06-06
FI930658A0 (fi)	1993-02-15
DE69126710T2 (de)	1998-01-15
JP2708960B2 (ja)	1998-02-04
KR970005273B1 (ko)	1997-04-15
DE69126710D1 (de)	1997-08-07
NO930515D0 (no)	1993-02-12
AU649717B2 (en)	1994-06-02
FI930658A7 (fi)	1993-02-15
HUT63430A (en)	1993-08-30
HU9300398D0 (en)	1993-05-28
CA2089666C (en)	2003-01-07
AU8439391A (en)	1992-03-17
DK0544713T3 (da)	1997-09-29
GR3024873T3 (en)	1998-01-30
FI930658L (fi)	1993-02-15
ES2104717T3 (es)	1997-10-16
WO1992003456A1 (en)	1992-03-05
EP0544713A4 (en)	1994-05-18
KR930701465A (ko)	1993-06-11

Legal Events

Date	Code	Title	Description
1997-11-15	UEP	Publication of translation of european patent specification
2006-05-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69126710D1 (de)	1997-08-07	Oligonukleotide zur modulation der effekte von cytomegalovirusinfektionen
DE69403642D1 (de)	1997-07-10	7-deazapurin modifizierte oligonukleotide
ATE261984T1 (de)	2004-04-15	N-2 substituierte purine
ATE289200T1 (de)	2005-03-15	Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
DE69228247D1 (de)	1999-03-04	Behandlung von Zellpopulationen
DE69840748D1 (de)	2009-05-28	Verfahren zur zubereitung von antisense oligonukleotiden
ATE244506T1 (de)	2003-07-15	Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein
FI925103A0 (fi)	1992-11-10	Antisense-inhibitorer av humant immunbristvirus
DE69927495D1 (de)	2006-02-09	Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide
DE58908694D1 (de)	1995-01-12	Oligonucleotidbank und verfahren zur dna-sequenzierung.
ATE189264T1 (de)	2000-02-15	Chimärisches oligonukleotid und dessen verwendung zur herstellung von nukleinsäure-transkripten
ATE352639T1 (de)	2007-02-15	Antisense modulation der expression von integrin alpha 4
DE69032080D1 (de)	1998-04-09	Verwendung von konservierten Oligonukleotid-Primern zur Amplifizierung von menschlichen Papillomavirus-DNS-Sequenzen
DE59309183D1 (de)	1999-01-14	Simultane sequenzierung von nukleinsäuren
DE69823372T8 (de)	2005-11-03	Verfahren und reagentiensatz zur amplifizierung, sequenzierung und typisierung von hla i genen
ATE212382T1 (de)	2002-02-15	Verfahren zur sequenzierung durch oligomerhybridisierung
DE68926455D1 (de)	1996-06-13	Verfahren zur identifizierung von bakterien
DE69434569D1 (de)	2006-01-12	Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel
IL98273A0 (en)	1992-06-21	Dna sequences,proteins having esterase activity coded by them,and use of such proteins
ATE337404T1 (de)	2006-09-15	Zur verleihung viraler resistenz an pflanzen geeignetes polyribozym und dieses polyribozym produzierende resistente pflanzen
ATE212057T1 (de)	2002-02-15	Ribozymstruktur die von den genomischen rns des hepatitis delta virus abgeleitet ist
DK727688A (da)	1989-07-01	Malariaspecifikke dna-sekvenser, deres expressionsprodukter samt anvendelsen heraf
ATE108834T1 (de)	1994-08-15	Spezifische nukleinsäurefragmente des menschlichen villingens, ihre anwendung für diagnostische zwecke.
ATE9005T1 (de)	1984-09-15	Dns-sequenzen, rekombinante dns-molekuele und verfahren zur herstellung von dem menschlichen interferon-alpha aehnlichen polypeptiden.
ATE87931T1 (de)	1993-04-15	Verfahren zur reinigung von spezifischen oligonukleotiden.